Differences between Human and Rat Intestinal and Hepatic Bisphenol A Glucuronidation and the Influence of Alamethicin on In Vitro Kinetic Measurements
Authors:
- Christopher S. MazurCMChristopher S. Mazur
- John F. KennekeJKJohn F. Kenneke
- Janet K. Hess-WilsonJHJanet K. Hess-Wilson
- John C. LipscombJLJohn C. Lipscomb
- 1 December 2010
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (12) , 2232-2238
Abstract
The extent to which membrane-disrupting agents, such as alamethicin, may alter cofactor transport and influence in vitro kinetic measurements of glucuronidation is a major concern regarding the characterization and extrapolation of inter- and intraspecies pharmacokinetics of bisphenol A (BPA). An additional concern is the omission of a BPA intestinal metabolism component in current pharmacokinetic models used to assess oral exposure. In this study, BPA glucuronidation in native hepatic microsomes from female rat and female human liver displayed higher Vmax values than that in males. In the presence of alamethicin, all hepatic Vmax values increased; however, this increase was disproportionately greater in males and gender differences were no longer observed. Female rats exhibited a much higher Km than all other species and genders; the addition of alamethicin had little influence on Km values for any of the test systems. The dissimilar Km measured for female rat suggests that different UDP-glucuronosyltransferase (UGT) enzyme(s) are involved in BPA glucuronidation. The presence of different UGTs in female rat was confirmed using Hill coefficients measured from diclofenac-mediated chemical inhibition assays within hepatic microsomes and purified human UGT2B7 and UGT2B15. Mixed-gender human intestinal microsomes showed little BPA glucuronidation reactivity compared with those from male rat intestine. Male rat intestinal microsomes in the presence of alamethicin exhibited a Vmax that was nearly 30-fold higher than that for mixed human microsomes. The species and gender metabolic differences we observed between rat and human liver and intestine provide key information for delineating BPA pharmacokinetics needed for human health risk assessment.Keywords
This publication has 34 references indexed in Scilit:
- Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancerCancer Causes & Control, 2009
- Predicting Plasma Concentrations of Bisphenol A in Children Younger Than 2 Years of Age after Typical Feeding Schedules, using a Physiologically Based Toxicokinetic ModelEnvironmental Health Perspectives, 2009
- Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug ClearancePharmaceutical Research, 2009
- Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidationChemosphere, 2008
- Scaling Factors for the Extrapolation of In Vivo Metabolic Drug Clearance From In Vitro Data: Reaching a Consensus on Values of Human Micro-somal Protein and Hepatocellularity Per Gram of LiverCurrent Drug Metabolism, 2007
- Identification of human UDP‐glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3‐hydroxydesloratadineBiopharmaceutics & Drug Disposition, 2004
- The Influence of Nonspecific Microsomal Binding on Apparent Intrinsic Clearance, and Its Prediction from Physicochemical PropertiesDrug Metabolism and Disposition, 2002
- Distribution and unspecific protein binding of the xenoestrogens bisphenol A and daidzeinArchives of Toxicology, 2002
- The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†Drug Metabolism Reviews, 2001
- Prediction of Hepatic Clearance from Microsomes, Hepatocytes, and Liver SlicesDrug Metabolism Reviews, 1997